Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Current Assets (2016 - 2025)

BioCorRx's Current Assets history spans 16 years, with the latest figure at $1.5 million for Q3 2025.

  • For Q3 2025, Current Assets rose 314.1% year-over-year to $1.5 million; the TTM value through Sep 2025 reached $1.5 million, up 314.1%, while the annual FY2024 figure was $117996.0, 36.94% down from the prior year.
  • Current Assets for Q3 2025 was $1.5 million at BioCorRx, up from $527483.0 in the prior quarter.
  • Across five years, Current Assets topped out at $2.0 million in Q1 2021 and bottomed at $117996.0 in Q4 2024.
  • The 5-year median for Current Assets is $353097.0 (2024), against an average of $536003.3.
  • The largest annual shift saw Current Assets plummeted 76.58% in 2021 before it skyrocketed 314.1% in 2025.
  • A 5-year view of Current Assets shows it stood at $228326.0 in 2021, then skyrocketed by 38.8% to $316910.0 in 2022, then tumbled by 40.96% to $187119.0 in 2023, then tumbled by 36.94% to $117996.0 in 2024, then skyrocketed by 1139.17% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BICX's Current Assets are $1.5 million (Q3 2025), $527483.0 (Q2 2025), and $565796.0 (Q1 2025).